$PCVX News

Vaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

Vaxcyte Q1 EPS $(2.30) Misses $(1.82) Estimate

Vaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV Market

Vaxcyte Inc (PCVX)’s VAX-31 Enters Critical Trial Stage

Is It Too Late To Consider Vaxcyte (PCVX) After A 95% One-Year Share Price Jump?

Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference

Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Vaxcyte Hits Enrollment Cap For Phase 3 Trials For VAX-31, A Pneumococcal Conjugate Vaccine Candidate

High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding

Reported Earlier, Vaxcyte's VAX-31 Demonstrates Robust Immune Responses Across All 31 Serotypes In Lancet-Published Phase 1/2 Adult Study Versus Prevnar 20

Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

Does Heavy 2025 Loss and Large Equity Raise for Vaxcyte’s VAX-31 Shift the Bull Case (PCVX)?

Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock.

Vaxcyte Advances VAX-31 Toward Phase 3 As Valuation Gap Persists

A Look At Vaxcyte (PCVX) Valuation As Share Price Momentum Rebuilds

BTIG Maintains Buy on Vaxcyte, Raises Price Target to $89

Vaxcyte, Inc. Q4 2025 Earnings Call Summary

Vaxcyte Q4 Earnings Call Highlights

Vaxcyte Inc (PCVX) Q4 2025 Earnings Call Highlights: Unprecedented Phase 2 Results and ...